Matches in Wikidata for { <http://www.wikidata.org/entity/Q66389629> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q66389629 description "clinical trial" @default.
- Q66389629 description "ensayu clínicu" @default.
- Q66389629 description "klinisch onderzoek" @default.
- Q66389629 description "клінічне випробування" @default.
- Q66389629 name "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 name "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 type Item @default.
- Q66389629 label "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 label "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 prefLabel "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 prefLabel "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differen" @default.
- Q66389629 P1050 Q66389629-B03AB656-BAB4-4272-999B-334FDF6E0765 @default.
- Q66389629 P1132 Q66389629-14E7BB6D-698A-486D-ADDB-9DAA61AF2E7D @default.
- Q66389629 P1476 Q66389629-42782308-24E5-4706-966B-5AEB34CD4E31 @default.
- Q66389629 P17 Q66389629-276ED58D-D9F7-443B-BF09-5DEB2EAC12C0 @default.
- Q66389629 P17 Q66389629-46809DB9-0C5E-42BE-AA52-4838FCC26EFE @default.
- Q66389629 P17 Q66389629-64E530EE-EB38-428C-9EBD-DAD763310CB5 @default.
- Q66389629 P17 Q66389629-B52CAE6A-8B5F-4FD3-B282-AFD765D296B5 @default.
- Q66389629 P17 Q66389629-C07B84C7-9AA3-4D5E-8FD8-0829FB6B99CB @default.
- Q66389629 P17 Q66389629-F32698BD-9A3E-4ED7-9E0A-3A043C39C5CC @default.
- Q66389629 P17 Q66389629-F9412121-96A8-460A-830E-22125AE007E3 @default.
- Q66389629 P1813 Q66389629-0B8B0B45-DCF9-46CB-9A7C-C68F69FAF233 @default.
- Q66389629 P2899 Q66389629-D1FB09DF-28DD-429F-9780-DF9FBE596EBA @default.
- Q66389629 P3098 Q66389629-26B333AD-CAEF-46A9-8734-5CEFB0CFC69A @default.
- Q66389629 P31 Q66389629-2FCD0A71-750A-416D-A219-CCC512D05B3A @default.
- Q66389629 P4844 Q66389629-C8D25AEA-C073-4BE4-A1EF-486FA52FB224 @default.
- Q66389629 P580 Q66389629-301D8869-7553-44E1-83CC-64B7DFDB78EF @default.
- Q66389629 P582 Q66389629-BF980E92-51FE-4DBA-AD37-B5A8E32FE4F1 @default.
- Q66389629 P8363 Q66389629-4DA3C0A1-CCBC-43E9-9C6E-FC3C04F4B60A @default.
- Q66389629 P1050 Q467635 @default.
- Q66389629 P1132 "+230" @default.
- Q66389629 P1476 "A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment" @default.
- Q66389629 P17 Q142 @default.
- Q66389629 P17 Q145 @default.
- Q66389629 P17 Q183 @default.
- Q66389629 P17 Q31 @default.
- Q66389629 P17 Q34 @default.
- Q66389629 P17 Q38 @default.
- Q66389629 P17 Q55 @default.
- Q66389629 P1813 "LocoMMotion" @default.
- Q66389629 P2899 "+18" @default.
- Q66389629 P3098 "NCT04035226" @default.
- Q66389629 P31 Q30612 @default.
- Q66389629 P4844 Q50429626 @default.
- Q66389629 P580 "2019-08-01T00:00:00Z" @default.
- Q66389629 P582 "2022-04-28T00:00:00Z" @default.
- Q66389629 P8363 Q818574 @default.